clinical trial · NCT06795009
Zanzalintinib in Combination With Paclitaxel in Recurrent High Grade Uterine Cancer
Uterine CancerEndometrial CancerZanzalintinibPaclitaxel
brief summary
The purpose of this study is to determine the recommended Phase 2 dose of zanzalintinib when given in combination with paclitaxel in patients with recurrent high-grade uterine cancer. Other objectives include overall safety and tolerability as well as rates of response.
started
Oct 17, 2025
primary completion
Nov 30, 2029
completion
Apr 30, 2035
last updated
Dec 11, 2025
official title
Phase I/IB Study of Zanzalintinib in Combination With Paclitaxel in Recurrent High Grade Uterine Cancer
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol